Juliana H. VanderPluym, M.D.

Closed for Enrollment

• A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II) Scottsdale/Phoenix, Ariz.

  The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.

• Digital biomarkers for objectively and remotely monitoring migraine: Changes in the King-Devick Test as a Predictor of Migraine Attack Onset Scottsdale/Phoenix, Ariz.

  Changes in vision are commonly reported by patients during migraine attacks. Even in patients that do not report changes in vision, we have noted objective changes as demonstrated by changes in the King-Devick Test (KDT), a quantitative measure of rapid eye movement; which was 6.5 seconds slower (SD 7.6 seconds, p<0.001) during a migraine attack compared to between migraine attacks. This study aims to evaluate changes in timed rapid number naming using the KDT during the twelve hours prior to a migraine attack (“pre-attack” phase) and during the migraine attack compared to the between attack phase. Accurate prediction of an impending migraine attack based on changes in the KDT would allow for future studies that determine the effectiveness of proactively treating migraine attacks during the very early “pre-symptomatic” stage, a strategy that would likely provide superior outcomes compared to current standard-of-care.

• STATUS STUDY: Pilot Open-Label Trial of Intravenous Erenumab in Patients with Status Migrainosus Scottsdale/Phoenix, Ariz.

  The purpose of this study is to investigate the use of erenumab 140mg IV in patients with status migrainosus. The specific aims of the study are to evaluate early endpoints of response including pain freedom at 2 hours, absence of the most bothersome symptom (MBS) at 2 hours, change in pain severity at 2 hours, and sustained pain freedom at 24 hours, and to evaluate late endpoints of response including change in migraine days at 4 weeks compared to baseline report, change in headache days at 4 weeks compared to baseline report, and change in acute medication use.

• The King-Devick Test (KDT) and Visual Contrast Sensitivity Test (VCS) in Migraine: The Effect of Migraine Attack on Rapid Eye Movements and Visual Sensitivity Scottsdale/Phoenix, Ariz.

  This research study is being done to help determine if King-Devick test (KDT) and Visual Contrast Sensitivity (VCS) can detect migraine-induced cerebral function changes.